Interventional pharmacoeconomics

Daniel A. Goldstein; Garth W. Strohbehn; Anthony V. Serritella; David A. Hyman; Allen S. Lichter; Mark J. Ratain

doi:10.1097/PPO.0000000000000461

Interventional pharmacoeconomics

Daniel A. Goldstein^*, Garth W. Strohbehn, Anthony V. Serritella, David A. Hyman, Allen S. Lichter, Mark J. Ratain

^*Corresponding author for this work

Medicine, Hospital Medicine Division

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

The increasing cost of health care is a major challenge around the world, but particularly in the United States. One reason for increased costs is the rapidly rising cost of oncology drugs. Potential solutions to this problem involve broad changes to health policy. However, an alternative solution is the development of lower-cost off-label treatment regimens, based on pharmacologic rationale, with significant potential economic impact. The pharmacologic and clinical properties of many drugs allow for a variety of different strategies. We describe this approach of interventional pharmacoeconomics and provide multiple individual examples.

Original language	English (US)
Pages (from-to)	330-334
Number of pages	5
Journal	Cancer Journal (United States)
Volume	26
Issue number	4
DOIs	https://doi.org/10.1097/PPO.0000000000000461
State	Published - Jul 1 2020

Funding

From the *Tel Aviv University, Tel Aviv; and †Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel; ‡Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC; §Value in Cancer Care Consortium, Ann Arbor, MI; ||Section of Hematology/Oncology, University of Chicago Medicine, Chicago, IL; and ¶Georgetown University Law Center, Washington, DC. Conflicts of Interest and Source of Funding: G.W.S. is supported by the Richard and Debra Gonzalez Research Fellowship at the University of Chicago (established through philanthropy by Abbott Laboratories, Lake Bluff, IL). M.J.R. has served as a patent litigation consultant and expert witness on behalf of multiple generic pharmaceutical companies and has received consulting fees from Ascentage, Aptevo, Pneuma Respiratory, and Shionogi; clinical trial funding from AbbVie, Dicerna, and Genentech; and other support from BeiGene. For the remaining authors, none were declared. Reprints: Daniel A. Goldstein, MD, Davidoff Center, Rabin Medical Center, 39 Jabotinsky Street, Petach Tikvah, Israel. E‐mail: [email protected]. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved. ISSN: 1528-9117

Keywords

Clinical trials
health policy
pharmacoeconomics
pharmacokinetics

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1097/PPO.0000000000000461

Cite this

@article{3bcd76f58b2542779a98c8aed98700e0,

title = "Interventional pharmacoeconomics",

abstract = "The increasing cost of health care is a major challenge around the world, but particularly in the United States. One reason for increased costs is the rapidly rising cost of oncology drugs. Potential solutions to this problem involve broad changes to health policy. However, an alternative solution is the development of lower-cost off-label treatment regimens, based on pharmacologic rationale, with significant potential economic impact. The pharmacologic and clinical properties of many drugs allow for a variety of different strategies. We describe this approach of interventional pharmacoeconomics and provide multiple individual examples. ",

keywords = "Clinical trials, health policy, pharmacoeconomics, pharmacokinetics",

author = "Goldstein, {Daniel A.} and Strohbehn, {Garth W.} and Serritella, {Anthony V.} and Hyman, {David A.} and Lichter, {Allen S.} and Ratain, {Mark J.}",

note = "Funding Information: From the *Tel Aviv University, Tel Aviv; and †Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel; ‡Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC; §Value in Cancer Care Consortium, Ann Arbor, MI; ||Section of Hematology/Oncology, University of Chicago Medicine, Chicago, IL; and ¶Georgetown University Law Center, Washington, DC. Conflicts of Interest and Source of Funding: G.W.S. is supported by the Richard and Debra Gonzalez Research Fellowship at the University of Chicago (established through philanthropy by Abbott Laboratories, Lake Bluff, IL). M.J.R. has served as a patent litigation consultant and expert witness on behalf of multiple generic pharmaceutical companies and has received consulting fees from Ascentage, Aptevo, Pneuma Respiratory, and Shionogi; clinical trial funding from AbbVie, Dicerna, and Genentech; and other support from BeiGene. For the remaining authors, none were declared. Reprints: Daniel A. Goldstein, MD, Davidoff Center, Rabin Medical Center, 39 Jabotinsky Street, Petach Tikvah, Israel. E‐mail: [email protected]. Copyright {\textcopyright} 2020 Wolters Kluwer Health, Inc. All rights reserved. ISSN: 1528-9117 Publisher Copyright: {\textcopyright} Wolters Kluwer Health, Inc. All rights reserved.",

year = "2020",

month = jul,

day = "1",

doi = "10.1097/PPO.0000000000000461",

language = "English (US)",

volume = "26",

pages = "330--334",

journal = "Cancer Journal (United States)",

issn = "1528-9117",

publisher = "Association Pour le Developpement de la Communication Cancerologique",

number = "4",

}

TY - JOUR

T1 - Interventional pharmacoeconomics

AU - Goldstein, Daniel A.

AU - Strohbehn, Garth W.

AU - Serritella, Anthony V.

AU - Hyman, David A.

AU - Lichter, Allen S.

AU - Ratain, Mark J.

N1 - Funding Information: From the *Tel Aviv University, Tel Aviv; and †Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel; ‡Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC; §Value in Cancer Care Consortium, Ann Arbor, MI; ||Section of Hematology/Oncology, University of Chicago Medicine, Chicago, IL; and ¶Georgetown University Law Center, Washington, DC. Conflicts of Interest and Source of Funding: G.W.S. is supported by the Richard and Debra Gonzalez Research Fellowship at the University of Chicago (established through philanthropy by Abbott Laboratories, Lake Bluff, IL). M.J.R. has served as a patent litigation consultant and expert witness on behalf of multiple generic pharmaceutical companies and has received consulting fees from Ascentage, Aptevo, Pneuma Respiratory, and Shionogi; clinical trial funding from AbbVie, Dicerna, and Genentech; and other support from BeiGene. For the remaining authors, none were declared. Reprints: Daniel A. Goldstein, MD, Davidoff Center, Rabin Medical Center, 39 Jabotinsky Street, Petach Tikvah, Israel. E‐mail: [email protected]. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved. ISSN: 1528-9117 Publisher Copyright: © Wolters Kluwer Health, Inc. All rights reserved.

PY - 2020/7/1

Y1 - 2020/7/1

N2 - The increasing cost of health care is a major challenge around the world, but particularly in the United States. One reason for increased costs is the rapidly rising cost of oncology drugs. Potential solutions to this problem involve broad changes to health policy. However, an alternative solution is the development of lower-cost off-label treatment regimens, based on pharmacologic rationale, with significant potential economic impact. The pharmacologic and clinical properties of many drugs allow for a variety of different strategies. We describe this approach of interventional pharmacoeconomics and provide multiple individual examples.

AB - The increasing cost of health care is a major challenge around the world, but particularly in the United States. One reason for increased costs is the rapidly rising cost of oncology drugs. Potential solutions to this problem involve broad changes to health policy. However, an alternative solution is the development of lower-cost off-label treatment regimens, based on pharmacologic rationale, with significant potential economic impact. The pharmacologic and clinical properties of many drugs allow for a variety of different strategies. We describe this approach of interventional pharmacoeconomics and provide multiple individual examples.

KW - Clinical trials

KW - health policy

KW - pharmacoeconomics

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=85088885498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088885498&partnerID=8YFLogxK

U2 - 10.1097/PPO.0000000000000461

DO - 10.1097/PPO.0000000000000461

M3 - Review article

C2 - 32732676

AN - SCOPUS:85088885498

SN - 1528-9117

VL - 26

SP - 330

EP - 334

JO - Cancer Journal (United States)

JF - Cancer Journal (United States)

IS - 4

ER -

Interventional pharmacoeconomics

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this